{"log_id": 5160832826014899341, "direction": 0, "words_result_num": 35, "words_result": [{"probability": {"variance": 0.005963, "average": 0.985912, "min": 0.497993}, "location": {"width": 775, "top": 143, "height": 40, "left": 213}, "words": "倍时,未观察到对心电图的影响,包括QT和QTe间期。在大鼠中进行的重复给药安全药理"}, {"probability": {"variance": 0.001395, "average": 0.992215, "min": 0.762414}, "location": {"width": 756, "top": 189, "height": 38, "left": 215}, "words": "学试验中,当全身暴露量是人治疗剂量暴露量的14倍时,超声心动图未提示心脏失代偿"}, {"probability": {"variance": 0, "average": 0.998614, "min": 0.998614}, "location": {"width": 39, "top": 208, "height": 30, "left": 1110}, "words": "文"}, {"probability": {"variance": 0.003502, "average": 0.985077, "min": 0.682821}, "location": {"width": 780, "top": 234, "height": 40, "left": 217}, "words": "在大鼠和猴中,当全身暴露量分别为人治疗剂量暴露量的1.4倍和4.6倍时,可观察到收缩压"}, {"probability": {"variance": 3.3e-05, "average": 0.996327, "min": 0.976451}, "location": {"width": 247, "top": 291, "height": 24, "left": 220}, "words": "和动脉血压升高(29mmHg)"}, {"probability": {"variance": 2e-06, "average": 0.998847, "min": 0.995771}, "location": {"width": 126, "top": 336, "height": 26, "left": 229}, "words": "【药代动力学】"}, {"probability": {"variance": 0.000144, "average": 0.994739, "min": 0.951162}, "location": {"width": 300, "top": 377, "height": 31, "left": 258}, "words": "泊沙康唑是一种三唑类抗真菌药物"}, {"probability": {"variance": 3.1e-05, "average": 0.997436, "min": 0.974288}, "location": {"width": 740, "top": 406, "height": 38, "left": 260}, "words": "剂量效应关系研究表明,在免疫缺陷患者参加的临床研究中,泊沙康唑血浆暴露水平"}, {"probability": {"variance": 8.5e-05, "average": 0.994392, "min": 0.959977}, "location": {"width": 780, "top": 444, "height": 40, "left": 220}, "words": "的范围较大。对患者数据的药代动力学药效学分析表明,平均泊沙康唑浓度(Cav)和预防"}, {"probability": {"variance": 0.004218, "average": 0.980658, "min": 0.622074}, "location": {"width": 775, "top": 483, "height": 41, "left": 221}, "words": "有效性之间存在明显的相关性。较低的Cay可增加治疗失败的风险[在研究中定义为停止治"}, {"probability": {"variance": 0.007082, "average": 0.96923, "min": 0.533303}, "location": {"width": 588, "top": 526, "height": 37, "left": 221}, "words": "疗、使用经验性全身抗真菌治疗(SAF)或侵袭性真菌感染(IFI)]。"}, {"probability": {"variance": 4.9e-05, "average": 0.996832, "min": 0.966704}, "location": {"width": 416, "top": 566, "height": 35, "left": 263}, "words": "为了增加泊沙康唑的口服吸收并且优化血浆浓度"}, {"probability": {"variance": 1.6e-05, "average": 0.995994, "min": 0.981886}, "location": {"width": 739, "top": 611, "height": 39, "left": 266}, "words": "1)必须在进餐期间或进餐后立即(20分钟内)服用本品。对于无法进餐的患者,可以"}, {"probability": {"variance": 0.000101, "average": 0.995096, "min": 0.953871}, "location": {"width": 781, "top": 658, "height": 39, "left": 226}, "words": "伴随营养液或碳酸饮料(如:姜汁汽水)服用本品。而对于无法进餐或不能耐受口服营养液"}, {"probability": {"variance": 7.3e-05, "average": 0.99703, "min": 0.945144}, "location": {"width": 781, "top": 702, "height": 41, "left": 228}, "words": "或碳酸饮料的患者,考虑采用其他抗真菌治疗或对患者出现的突破性真菌感染进行密切监测"}, {"probability": {"variance": 0.008086, "average": 0.979277, "min": 0.451051}, "location": {"width": 708, "top": 729, "height": 58, "left": 267}, "words": "2)在出现重度腹泻或呕吐的患者中,必须对突破性真菌感染进行密切监次PHAR"}, {"probability": {"variance": 0.002631, "average": 0.986494, "min": 0.695166}, "location": {"width": 741, "top": 789, "height": 42, "left": 267}, "words": "3)除非收益超过风险,通常应避免可导致泊沙康唑血浆浓度降低的联合用药。如果需"}, {"probability": {"variance": 0.002391, "average": 0.990318, "min": 0.693085}, "location": {"width": 769, "top": 835, "height": 41, "left": 229}, "words": "要使用这类药物,必须对患者出现的突破性真菌感染进行密切监测【见药物相互作用章"}, {"probability": {"variance": 0, "average": 0.999268, "min": 0.99909}, "location": {"width": 45, "top": 894, "height": 24, "left": 269}, "words": "吸收"}, {"probability": {"variance": 0.000121, "average": 0.995256, "min": 0.949807}, "location": {"width": 742, "top": 926, "height": 41, "left": 271}, "words": "在免疫缺陷患者参加的临床研究中,泊沙康唑血浆暴露水平的范围较大。对患者数据的"}, {"probability": {"variance": 0.005535, "average": 0.980671, "min": 0.56012}, "location": {"width": 781, "top": 973, "height": 41, "left": 234}, "words": "药代动力学药效学分析表明,平均泊沙康唑浓度(Cay)和预防有效性之间存在明显的相关"}, {"probability": {"variance": 0.003744, "average": 0.982244, "min": 0.621177}, "location": {"width": 779, "top": 1018, "height": 40, "left": 234}, "words": "性。较低的Cav可增加治疗失败的风险[在研究中定义为停止治疗、使用经验性全身抗真菌治"}, {"probability": {"variance": 0.002711, "average": 0.973318, "min": 0.796042}, "location": {"width": 333, "top": 1070, "height": 33, "left": 233}, "words": "疗(SAF)或侵袭性真菌感染(IFI)]"}, {"probability": {"variance": 0.028315, "average": 0.575945, "min": 0.421375}, "location": {"width": 94, "top": 1052, "height": 46, "left": 897}, "words": "约晨"}, {"probability": {"variance": 0.005619, "average": 0.973201, "min": 0.651643}, "location": {"width": 738, "top": 1098, "height": 40, "left": 275}, "words": "泊沙康唑吸收时的Tmx中位值约为3至5小时。单次口服50mg至800mg和多次口搬"}, {"probability": {"variance": 0.004837, "average": 0.978124, "min": 0.550578}, "location": {"width": 782, "top": 1136, "height": 47, "left": 235}, "words": "50mg,每日2次至400mg,每日2次后,泊沙康唑的血浆暴露水平(AUC与剂量成比"}, {"probability": {"variance": 0.000344, "average": 0.994272, "min": 0.881877}, "location": {"width": 783, "top": 1178, "height": 42, "left": 238}, "words": "例增加。在发热性中性粒细胞减少症患者或难治性侵袭性真菌感染患者中,当剂量从400"}, {"probability": {"variance": 0.00141, "average": 0.989574, "min": 0.759945}, "location": {"width": 776, "top": 1217, "height": 41, "left": 239}, "words": "每日2次增至600mg,每日2次时,未观察到暴露水平进一步增加。多次给药后至10天"}, {"probability": {"variance": 1.2e-05, "average": 0.997431, "min": 0.988678}, "location": {"width": 170, "top": 1267, "height": 27, "left": 248}, "words": "可达到稳态血浆浓度"}, {"probability": {"variance": 4.1e-05, "average": 0.996776, "min": 0.962852}, "location": {"width": 728, "top": 1297, "height": 37, "left": 280}, "words": "在摄入非高脂肪膳食和高脂膳食(约50gm脂肪)的情况下单次服用200mg剂量后"}, {"probability": {"variance": 0.000145, "average": 0.995221, "min": 0.930603}, "location": {"width": 779, "top": 1334, "height": 39, "left": 240}, "words": "泊沙康唑的平均AUC和Cmx分别约为空腹状态下的3倍和4倍。在摄入营养液(14gm脂"}, {"probability": {"variance": 0.001949, "average": 0.984188, "min": 0.721512}, "location": {"width": 776, "top": 1374, "height": 40, "left": 241}, "words": "肪)的情况下单次口服400mg后,泊沙康唑的平均AUC和Cmax约为空腹状态下的3倍(参"}, {"probability": {"variance": 0.000196, "average": 0.994883, "min": 0.915769}, "location": {"width": 672, "top": 1415, "height": 37, "left": 243}, "words": "见表9)。为确保达到适当的血浆浓度,建议摄食或摄入营养液后服用泊沙康唑"}, {"probability": {"variance": 0.042474, "average": 0.728814, "min": 0.492107}, "location": {"width": 144, "top": 1465, "height": 54, "left": 780}, "words": "美冷酸"}, {"probability": {"variance": 0.028895, "average": 0.693032, "min": 0.535967}, "location": {"width": 50, "top": 1506, "height": 21, "left": 806}, "words": "有限公"}], "language": 3}